Eden Research (EDEN)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 4.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 11.85
  • 52 Week Low: 3.40
  • Currency: UK Pounds
  • Shares Issued: 533.35m
  • Volume: 255,065
  • Market Cap: £22.67m

Eden Research bounces on first commercial order for Mevalone

By Oliver Haill

Date: Wednesday 10 Feb 2016

LONDON (ShareCast) - (ShareCast News) - Eden Research has received its first order for its Mevalone grape crop treatment from partner K&N Efthymiadis that will generate first revenue from the agreement.
K&N Efthymiadis, which is an arm of Greek agribusiness group Redestos, has placed placed its first order for Mevalone for the prevention and cure of botrytis on table and wine grapes in Greece, with plans to expand this quickly for a wider range of crops.

The companies said this was an important step in the commercialisation of one of the first terpene-based products in the agricultural market.

Mevalone is the trade name used in several countries for AIM-listed Eden's fungicidal agrochemical product, 3AEY, and this order follows the national approval for commercial sale in Greece received in August 2015.

Eden, which specialises in 'microencapsulation' technologies for the global agrochemicals, animal health and consumer products industries, will supply KNE with Mevalone, with Eden then generating revenue from product sales made by the Greek company and royalties based on net sales from this first order.

Chief executive Sean Smith, said 2016 is expected to be a year of tremendous progress for Eden and its partners commercial sales begin.

"Our licensees and distributors are now able to realise the initial potential of Eden's product pipeline, and with further label extensions and partnerships to come, we are pleased with the prospects for the future.

"KNE are now executing a comprehensive commercialisation plan across their territories, and we look forward to working with them to support their ambitions. Furthermore, we are also actively collaborating to expand commercialisation activities beyond Mevalone thereby building future growth into our relationship."

Having sunk to nine-month lows with no explanation on Tuesday, shares in Eden bounced 24% higher at 10.42p by mid afternoon on Wednesday, around the level they were last May.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Eden Research Market Data

Currency UK Pounds
Share Price 4.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 11.85
52 Week Low 3.40
Volume 255,065
Shares Issued 533.35m
Market Cap £22.67m

Eden Research Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
33.98% below the market average33.98% below the market average33.98% below the market average33.98% below the market average33.98% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income Not Available
Growth
5.67% above the market average5.67% above the market average5.67% above the market average5.67% above the market average5.67% above the market average
5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average5.56% above the sector average

Eden Research Dividends

No dividends found

Trades for 26-Apr-2024

Time Volume / Share Price
15:25 10,000 @ 4.33p
13:14 8,000 @ 4.33p
12:31 15,000 @ 4.34p
12:18 7,533 @ 4.34p
12:18 7,936 @ 4.17p

Eden Research Key Personnel

CFO Alexander John Abrey
CEO Sean M. Smith

Top of Page